Search Results
207 results
Your search is now limited to «Biogen» expert search.
MarketWatch 03/25/2019 06:26
Biogen sets new $5 billion stock repurchase program in aftermath of stock plunge.
More from MarketWatch:
NASDAQ 03/23/2019 11:07
These two takeout targets have what team Biogen's looking for -- plus there's a good chance acquiring them could also work out well for Biogen's shareholders down the line.
More from NASDAQ:
ENDPOINTS 03/23/2019 10:53
The question now is whether Eisai will be part of Biogen’s future.
More from ENDPOINTS:
Investor's Business Daily 03/22/2019 16:47
Biogen (BIIB) and Japan's Eisai announced a new study in Alzheimer's treatment Friday following a high-profile failure this week that sent Biogen stock into a tailspin.
More from Investor's Business Daily:
Market Exclusive 03/22/2019 13:20
Analyst Ratings For Biogen (NASDAQ:BIIB) Today, Barclays reiterated its Hold rating on Biogen (NASDAQ:BIIB) with a price target of $250.00. There are 21 Hold Ratings, 8 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock. The current consensus rating on Biogen (NASDAQ:BIIB) is Hold with a consensus target price of $317.1981 per […]. The post Biogen (NASDAQ:BIIB) had its Hold rating reiterated by Barclays with a $250.00 price target appeared first on Market Exclusive .
More from Market Exclusive:
Contract Pharma 03/22/2019 09:45
Biogen and Eisai, Co., Ltd. are discontinuing global Phase III trials, ENGAGE and EMERGE, evaluating the efficacy and safety of aducanumab in mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia.
More from Contract Pharma:
24/7 Wall Street 03/22/2019 08:45
Biogen Inc. (NASDAQ: BIIB) was downgraded by several firms on Thursday after dropping more than 29% to $226.88 because the company bombed out on its Alzheimer’s late-stage studies.
More from 24/7 Wall Street:
PMLiVE 03/22/2019 07:18
The move surprised investors who had already started reducing or removing BAN2401 from their future sales predictions for Eisai and partner Biogen, on the grounds that aducanumab’s failure was likely one of the final throws of the dice for the much-discredited amyloid hypothesis of AD.
More from PMLiVE:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications